133 related articles for article (PubMed ID: 38459158)
1. FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma.
Killock D
Nat Rev Clin Oncol; 2024 May; 21(5):335. PubMed ID: 38459158
[No Abstract] [Full Text] [Related]
2. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.
O'Kane GM; Ezzat S; Joshua AM; Bourdeau I; Leibowitz-Amit R; Olney HJ; Krzyzanowska M; Reuther D; Chin S; Wang L; Brooks K; Hansen AR; Asa SL; Knox JJ
Br J Cancer; 2019 Jun; 120(12):1113-1119. PubMed ID: 31105270
[TBL] [Abstract][Full Text] [Related]
3. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
Joshua AM; Ezzat S; Asa SL; Evans A; Broom R; Freeman M; Knox JJ
J Clin Endocrinol Metab; 2009 Jan; 94(1):5-9. PubMed ID: 19001511
[TBL] [Abstract][Full Text] [Related]
4. The role of pre-operative α-blockade in patients with normotensive phaeochromocytoma or paraganglioma: A retrospective cohort study.
Kong H; Li N; Li XY; Wang DX
Eur J Anaesthesiol; 2018 Nov; 35(11):898-899. PubMed ID: 30278035
[No Abstract] [Full Text] [Related]
5. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
Ayala-Ramirez M; Chougnet CN; Habra MA; Palmer JL; Leboulleux S; Cabanillas ME; Caramella C; Anderson P; Al Ghuzlan A; Waguespack SG; Deandreis D; Baudin E; Jimenez C
J Clin Endocrinol Metab; 2012 Nov; 97(11):4040-50. PubMed ID: 22965939
[TBL] [Abstract][Full Text] [Related]
6. Targeted molecular medicine: advances in the treatment of metastatic phaeochromocytoma and paraganglioma.
Naruse M; Young WF
Lancet; 2024 Mar; 403(10431):1001-1003. PubMed ID: 38402884
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan.
Naruse M; Satoh F; Tanabe A; Okamoto T; Ichihara A; Tsuiki M; Katabami T; Nomura M; Tanaka T; Matsuda T; Imai T; Yamada M; Harada T; Kawata N; Takekoshi K
Endocr J; 2018 Mar; 65(3):359-371. PubMed ID: 29353821
[TBL] [Abstract][Full Text] [Related]
8. [Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments].
Kukla U; Łabuzek K; Chronowska J; Bobrzyk M; Madej P; Okopień B
Pol Merkur Lekarski; 2015 Apr; 38(226):191-5. PubMed ID: 25938384
[TBL] [Abstract][Full Text] [Related]
9. Clinical features and outcomes of metastatic pheochromocytoma treated by cytotoxic chemotherapy.
Fujiwara Y; Ohmoto A; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Yuasa T; Yonese J; Takahashi S
Endocr J; 2021 Jun; 68(6):671-681. PubMed ID: 33518616
[TBL] [Abstract][Full Text] [Related]
10. Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.
Matro J; Giubellino A; Pacak K
Horm Metab Res; 2013 Feb; 45(2):147-53. PubMed ID: 23322515
[TBL] [Abstract][Full Text] [Related]
11. Systemic therapies for malignant pheochromocytoma and paraganglioma can exacerbate hypertension.
Fishbein L; Cohen DL
J Clin Hypertens (Greenwich); 2013 Jul; 15(7):513-4. PubMed ID: 23815541
[No Abstract] [Full Text] [Related]
12. Endocrine tumours.
Lamberts SW
Cancer Chemother Biol Response Modif; 1997; 17():492-503. PubMed ID: 9551228
[No Abstract] [Full Text] [Related]
13. Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I-metaiodobenzylguanidine.
Bomanji J; Britton KE; Ur E; Hawkins L; Grossman AB; Besser GM
Nucl Med Commun; 1993 Oct; 14(10):856-61. PubMed ID: 8233228
[TBL] [Abstract][Full Text] [Related]
14. Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience.
Shilkrut M; Bar-Deroma R; Bar-Sela G; Berniger A; Kuten A
Am J Clin Oncol; 2010 Feb; 33(1):79-82. PubMed ID: 19704370
[TBL] [Abstract][Full Text] [Related]
15. Niche for polyamine inhibition in treatment of metastatic pheochromocytoma and paraganglioma.
Ghayee HK; Hatch H; Bergeron RJ; Hadrava Vanova K; Pacak K; Tevosian S
Eur J Clin Invest; 2024 May; 54(5):e14162. PubMed ID: 38381501
[No Abstract] [Full Text] [Related]
16. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.
Baudin E; Goichot B; Berruti A; Hadoux J; Moalla S; Laboureau S; Nölting S; de la Fouchardière C; Kienitz T; Deutschbein T; Zovato S; Amar L; Haissaguerre M; Timmers H; Niccoli P; Faggiano A; Angokai M; Lamartina L; Luca F; Cosentini D; Hahner S; Beuschlein F; Attard M; Texier M; Fassnacht M; ;
Lancet; 2024 Mar; 403(10431):1061-1070. PubMed ID: 38402886
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients.
Hadoux J; Terroir M; Leboulleux S; Deschamps F; Al Ghuzlan A; Hescot S; Tselikas L; Borget I; Caramella C; Déandréis D; Goere D; De Baere T; Schlumberger M; Baudin E
Horm Cancer; 2017 Dec; 8(5-6):330-337. PubMed ID: 28748315
[TBL] [Abstract][Full Text] [Related]
18. Targeted Therapies in Pheochromocytoma and Paraganglioma.
Wang K; Crona J; Beuschlein F; Grossman AB; Pacak K; Nölting S
J Clin Endocrinol Metab; 2022 Nov; 107(11):2963-2972. PubMed ID: 35973976
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis.
Niemeijer ND; Alblas G; van Hulsteijn LT; Dekkers OM; Corssmit EP
Clin Endocrinol (Oxf); 2014 Nov; 81(5):642-51. PubMed ID: 25041164
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of systemic treatment according to germline mutational status in patients with metastatic pheochromocytoma and paraganglioma.
Park YG; Park I; Kim Y; Lee HS; Lee W; Yoon S; Lee JL
Clin Genitourin Cancer; 2024 Apr; 22(2):413-419. PubMed ID: 38228412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
